Do people with hemophilia face any obstacles to gaining access to these recombinant blood products?
The most crucial obstacle is the cost of such new products. The average annual cost of factor products derived from human plasma for a person with severe hemophilia is approximately $100,000. Recombinant factor VIII is priced significantly higher than plasma-derived products. Thus, lifetime insurance limits (“caps”) present significant difficulties for the use of recombinant products. Additionally, current supply shortages have prevented some persons with bleeding disorders from being able to utilize a recombinant FVIII product.
